Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Cabaletta Bio, Inc. (CABA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update"
05/11/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update"
03/16/2023 8-K Investor presentation, Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update",
"Cabaletta Bio, Inc. Corporate Presentation, furnished herewith"
11/10/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/17/2022 8-K Investor presentation, Quarterly results
Docs: "Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update",
"Cabaletta Bio, Inc. Corporate Presentation, furnished herewith"
11/01/2021 8-K Investor presentation, Quarterly results
Docs: "Cabaletta Bio Reports Third Quarter 2021 Financial Results and Provides Business Update",
"Cabaletta Bio, Inc. Corporate Presentation, dated November 2021, furnished herewith",
"Cabaletta Bio Reports Clinical Data from the Third Dose Cohort in DesCAARTes ™ Trial in Patients with mPV"
08/05/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 November 10, 2020 Date of Report CABALETTA BIO, INC. Delaware 001-39103 82-1685768 2929 Arch Street, Suite 600, Philadelphia, PA 19104 759-3100 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 ...",
"Cabaletta Bio Reports Third Quarter 2020 Financial Results and Provides Business Update"
08/06/2020 8-K Quarterly results
05/12/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 May 12, 2020 Date of Report CABALETTA BIO, INC. Delaware 001-39103 82-1685768 2929 Arch Street, Suite 600, Philadelphia, PA 19104 759-3100 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under...",
"Cabaletta Bio Reports First Quarter 2020 Financial Results and Provides Business Update"
03/30/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 March 30, 2020 Date of Report CABALETTA BIO, INC. Delaware 001-39103 82-1685768 2929 Arch Street, Suite 600, Philadelphia, PA 19104 759-3100 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 und...",
"Cabaletta Bio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy